Quantcast
Channel: BioTuesdays » liver failure
Browsing latest articles
Browse All 3 View Live

Image may be NSFW.
Clik here to view.

William Blair starts Vital Therapies at outperform

William Blair has initiated coverage of Vital Therapies (NASDAQ:VTL) with an “outperform” rating and a $28 price target. The stock closed at $12.34 on Friday. Analyst Katherine Xu writes that the...

View Article



Image may be NSFW.
Clik here to view.

WB ups Vital Therapies price target to $36

William Blair has raised its price target on “outperform-rated” Vital Therapies (NASDAQ:VTL) to $36 from $28, citing an update on the status of the ELAD clinical program and highlights from investor...

View Article

Image may be NSFW.
Clik here to view.

Vital Therapies prices follow-on offering


Vital Therapies (NASDAQ:VTL) has priced a follow-on public offering of two million common shares at a price of $17.50 each and granted underwriters a 30-day option to purchase up to an additional...

View Article
Browsing latest articles
Browse All 3 View Live




Latest Images